Oxoid and Remel, the world leading microbiology brands of Thermo Fisher Scientific, have introduced a complete portfolio of culture media for the microbiological examination of non-sterile pharmaceutical products, as recommended in the Harmonized Microbial Limit Tests chapters in the Ph. Eur, USP and JP.
Oxoid and Remel, the world leading microbiology brands of Thermo Fisher Scientific, have introduced a complete portfolio of culture media for the microbiological examination of non-sterile pharmaceutical products, as recommended in the Harmonized Microbial Limit Tests chapters in the Ph. Eur, USP and JP.
The fully validated portfolio (validation documents available on request) includes dehydrated culture media and prepared media for both microbial enumeration tests and specific micro-organism testing.
Rigorous quality assurance and quality control systems ensure that Oxoid and Remel media meet the technical specifications and regulatory standards that pharmaceutical microbiologists require. Carefully sourced raw materials are fully traceable. Quality control is performed quantitatively and qualitatively, using the recommended strains and incubation/temperature parameters outlined in the harmonized MLT chapters of the Ph. Eur, USP and JP. Pharmaceutical companies can therefore have complete confidence in the Oxoid and Remel portfolio.
Oxoid and Remel prepared media are produced in specialized production facilities* in the UK, Germany, USA, Canada and Australia. These units utilize state-of-the-art equipment and carefully controlled environments to ensure consistent, high-quality products made to the latest international standards. On-site inspections and audits are welcome and can be arranged through Oxoid and Remel representatives.
Find out more here.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.